Kazia Therapeutics (KZIA) Stock Price, News & Analysis

Company Overview

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Key Stats

• Today's Range: $5.50 to $5.87
• 50-Day Range: $3.20 to $6.78
• 52-Week Range: $1.87 to $15.80
• Volume: 7,222 shs
• Average Volume: 426,640 shs
• Market Capitalization: $14.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.00
• Consensus Rating: Buy

Kazia Therapeutics Stock Analysis - MarketRank™

Kazia Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 726th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kazia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kazia Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Kazia Therapeutics are expected to remain at ($3.30) per share in the coming year.

Price to Book Value per Share Ratio

Kazia Therapeutics has a P/B Ratio of 1.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.71% of the outstanding shares of Kazia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Kazia Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kazia Therapeutics has recently decreased by 88.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kazia Therapeutics does not currently pay a dividend.

Dividend Growth

Kazia Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.71% of the outstanding shares of Kazia Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Kazia Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kazia Therapeutics has recently decreased by 88.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for KZIA on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kazia Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.00% of the stock of Kazia Therapeutics is held by insiders.

Percentage Held by Institutions

Only 30.89% of the stock of Kazia Therapeutics is held by institutions.

KZIA Stock Analysis - Frequently Asked Questions

How have KZIA shares performed this year?

Kazia Therapeutics' stock was trading at $4.3950 at the beginning of 2024. Since then, KZIA stock has increased by 28.6% and is now trading at $5.65.
View the best growth stocks for 2024 here.

When did Kazia Therapeutics' stock split?

Kazia Therapeutics's stock reverse split before market open on Monday, October 28th 2024. The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Kazia Therapeutics' major shareholders?

Top institutional investors of Kazia Therapeutics include MAI Capital Management (51.66%).

How do I buy shares of Kazia Therapeutics?

Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kazia Therapeutics investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KZIA
• CUSIP: N/A
• CIK: 1075880
• Web: www.kaziatherapeutics.com
• Phone: (129) 472-4101
• Fax: 61-2-9476-0388
• Employees: 12
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $20.00
• High Stock Price Target: $20.00
• Low Stock Price Target: $20.00
• Potential Upside/Downside: +260.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.51 million
• Price / Sales: 9.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.96 per share
• Price / Book: 1.12

Miscellaneous

• Outstanding Shares: 2,640,000
• Free Float: 2,610,000
• Market Cap: $14.65 million
• Optionable: Optionable
• Beta: 2.08